Comparative Analysis of Dasatinib Effect between 2D and 3D Tumor Cell Cultures.

3D tissue culture 3D tumor model drug resistance drug screening preclinical study tumor spheroids

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
21 Jan 2023
Historique:
received: 15 12 2022
revised: 14 01 2023
accepted: 18 01 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

Three-dimensional cell culture methods are able to confer new predictive relevance to in vitro tumor models. In particular, the 3D multicellular tumor spheroids model is considered to better resemble tumor complexity associated with drug resistance compared to the 2D monolayer model. Recent advances in 3D printing techniques and suitable biomaterials have offered new promises in developing 3D tissue cultures at increased reproducibility and with high-throughput characteristics. In our study, we compared the sensitivity to dasatinib treatment in two different cancer cell lines, prostate cancer cells DU145 and glioblastoma cells U87, cultured in the 3D spheroids model and in the 3D bioprinting model. DU145 and U87 cells were able to proliferate in 3D alginate/gelatin bioprinted structures for two weeks, forming spheroid aggregates. The treatment with dasatinib demonstrated that bioprinted cells were considerably more resistant to drug toxicity than corresponding cells cultured in monolayer, in a way that was comparable to behavior observed in the 3D spheroids model. Recovery and analysis of cells from 3D bioprinted structures led us to hypothesize that dasatinib resistance was dependent on a scarce penetrance of the drug, a phenomenon commonly reported also in spheroids. In conclusion, the 3D bioprinted model utilizing alginate/gelatin hydrogel was demonstrated to be a suitable model in drug screening when spheroid growth is required, offering advantages in feasibility, reproducibility, and scalability compared to the classical 3D spheroids model.

Identifiants

pubmed: 36839692
pii: pharmaceutics15020372
doi: 10.3390/pharmaceutics15020372
pmc: PMC9967321
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : DISCAB - University of L'Aquila
ID : intramural research program

Références

Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Cancer Res. 2019 Nov 15;79(22):5702-5703
pubmed: 31772072
Oncol Lett. 2017 Dec;14(6):6999-7010
pubmed: 29344128
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80
pubmed: 12768623
Biomaterials. 2016 Sep;102:20-42
pubmed: 27318933
Clin Cancer Res. 2014 Oct 15;20(20):5265-71
pubmed: 25172932
Mol Carcinog. 2013 Mar;52(3):167-82
pubmed: 22162252
Assay Drug Dev Technol. 2019 Apr;17(3):140-149
pubmed: 30958703
J Med Chem. 2004 Dec 30;47(27):6658-61
pubmed: 15615512
Biomaterials. 2010 Nov;31(32):8494-506
pubmed: 20709389
Biomaterials. 2016 Jan;76:321-43
pubmed: 26561931
Toxicol Appl Pharmacol. 2011 Oct 1;256(1):62-72
pubmed: 21839104
Cancers (Basel). 2019 Apr 06;11(4):
pubmed: 30959887
Sci Rep. 2015 Jul 08;5:12175
pubmed: 26153550
Gels. 2022 Mar 14;8(3):
pubmed: 35323292
Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30
pubmed: 12020799
Cancer Metastasis Rev. 2003 Dec;22(4):337-58
pubmed: 12884910
PLoS One. 2015 Jun 19;10(6):e0130348
pubmed: 26090664
Cancers (Basel). 2020 Jun 02;12(6):
pubmed: 32498343
Nat Rev Cancer. 2004 Jun;4(6):470-80
pubmed: 15170449
Genes Dev. 1994 Sep 1;8(17):1999-2007
pubmed: 7958873
Nat Rev Clin Oncol. 2009 Oct;6(10):587-95
pubmed: 19787002
Cancer Cell Int. 2021 Mar 4;21(1):152
pubmed: 33663530

Auteurs

Samantha Sabetta (S)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Davide Vecchiotti (D)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Letizia Clementi (L)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Mauro Di Vito Nolfi (M)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Francesca Zazzeroni (F)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Adriano Angelucci (A)

Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.

Classifications MeSH